Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients.

ABSTRACT:

Aims

Radiofrequency catheter ablation (RFCA) is now an established therapeutic option for patients with atrial fibrillation (AF), but the long-term recurrence rate of AF is still high. Sacubitril/valsartan (Sac/Val) is superior to valsartan in attenuating ventricular remodelling and improving clinical outcomes in heart failure patients, but whether this additional benefit exists in reversing atrial remodelling and reducing AF recurrence of RFCA-treated AF patients remains uncovered.

Methods and results

Patients that had undergone RFCA were enrolled and randomly assigned 1:1 to valsartan (160 mg/day) or Sac/Val (200 mg/day) treatment group, in addition to other standard treatment of AF. Patients were followed up for 24 weeks. Echocardiography and ambulatory Holter monitoring

SUBMITTER: Yang L 

PROVIDER: S-EPMC9288756 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature